Oral vs. Injectable HMAs: Patient Perspectives, Access, and IRA Impact

Author(s):

Ryan Haumschild, PharmD, MS, MBA,James McCloskey, MD

Medical experts discuss innovations and future directions in treatments for higher-risk MDSMedical experts offer patient perspectives on advantages and disadvantages of using oral HMAs vs injectable HMAs.

EP: 1.Advances in MDS Classification and Molecular Understanding

EP: 2.Choosing MDS Therapies: Risk-Based Approaches

EP: 3.Luspatercept in Lower Risk MDS: Insights on the COMMANDS Trial

EP: 4.ASCERTAIN Data: Oral Decitabine-Cedazuridine Outcomes in MDS

EP: 5.Oral vs. Injectable HMAs: Convenience and Efficacy in Higher Risk MDS

EP: 6.HMA Persistence and Effectiveness in Higher Risk MDS

EP: 7.Innovations and Future Directions in Higher Risk MDS Treatments

Now Viewing

EP: 8.Oral vs. Injectable HMAs: Patient Perspectives, Access, and IRA Impact

EP: 9.Oral vs. IV HMAs: Considerations and Patient Guidance

EP: 10.Patient Feedback for MDS: Insights and Closing Remarks

Video content above is prompted by the following:

From a patient’s perspective, what are some of the advantages and disadvantages of using oral hypomethylating agents (HMAs) vs injectable HMAs?
How do you anticipate the Inflation Reduction Act’s out-of-pocket prescription drug cost cap will affect access to oral HMAs starting in 2025?

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe Now!